Opulus Lymphoma Precision
Overview
Opulus™ Lymphoma Precision is an AI-powered software tool developed by Roche Molecular Systems. It is designed to assist physicians in analyzing whole-body FDG-PET/CT scans of patients already diagnosed with FDG-avid lymphomas. The tool utilizes a machine learning methodology to automate the labor-intensive task of quantifying disease burden.
Key functionalities include the automatic segmentation and visualization of lymphoma lesions, as well as the calculation of the total metabolic tumor volume (TMTV). This supports physicians by reducing manual workload and facilitating more efficient interpretation of PET/CT images. It’s important to note that Opulus™ Lymphoma Precision is an assistive tool; it does not screen for or diagnose lymphoma, and the final clinical decisions remain with the interpreting radiologist. Physicians have the option to accept or reject the output generated by the device.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered software tool for PET/CT analysis
- Analyzes whole-body FDG-PET/CT scans
- Automatically segments lymphoma lesions
- Visualizes lymphoma lesions
- Calculates total metabolic tumor volume (TMTV)
- Uses machine learning methodology for lesion localization and segmentation
- Assists in efficient interpretation of PET/CT images
- Physician has option to accept/reject output
- Aids in quantifying disease burden
Use Cases
- Quantifying disease burden in patients already diagnosed with FDG-avid lymphomas
- Assisting physicians in the interpretation of FDG-PET/CT images for lymphoma
- Automating labor-intensive tasks of lesion quantification in PET/CT scans
- Visualization of suspected lymphoma lesions
- Calculation of total volume of all lesions in a body
What Physicians Need to Know
Opulus™ Lymphoma Precision is an assistive tool, meaning a radiologist's review is crucial for final interpretation of FDG-PET/CT scans. While the tool automates tedious quantification tasks, the physician retains the ability to accept or reject the generated output. This tool is specifically for patients already diagnosed with FDG-avid lymphoma and should not be used for screening or diagnosis. It can significantly improve efficiency in quantifying disease burden, allowing more focus on complex diagnostic challenges.
Roche is actively fostering an open digital pathology ecosystem, allowing for the integration of third-party AI algorithms with its navify® Digital Pathology software. This means that Opulus™ Lymphoma Precision, or similar future tools, could potentially be used alongside other AI-driven solutions from various developers within a unified workflow. Roche also makes its BIF file format specifications publicly available to encourage further innovation and integration.
Details
| Category | Oncology AI, Radiology & Imaging AI |
| Pricing |
Unknown
|
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status |
Cleared AI-estimated Opulus™ Lymphoma Precision received FDA 510(k) clearance on May 30, 2025. It is a software device that uses a machine learning-based algorithm to automate segmentation and visualization of lesions and calculate total metabolic tumor volume within whole-body FDG-PET/CT scans of patients with FDG-avid lymphomas. It is intended to assist trained interpreting physicians with visualization of suspected lesions and calculation of total volume of all lesions in a body. This information can be used in addition to other clinical information. |
| Integrations | |
| EHR | Not specified |
| Specialties | Nuclear Medicine, Oncology, Radiology |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2025-05-30 | K243863 510(k) | Opulus Lymphoma Precision |
What the Web Says
Opulus™ Lymphoma Precision is a software device developed by Roche Molecular Systems, Inc. that utilizes a machine learning-based algorithm to automate the segmentation and visualization of lesions, and to measure total metabolic tumor volume (TMTV) in whole-body FDG-PET/CT scans for patients diagnosed with FDG-avid lymphoma. This tool is designed to assist trained interpreting physicians in visualizing suspected lesions and calculating their total volume, which can be used in conjunction with standard image interpretation. The software aims to improve the efficiency of medical professionals by automating tasks that are otherwise tedious when performed manually.
Overall: PositiveStrengths
- Automates segmentation and visualization of lesions in FDG-PET/CT scans.
- Measures total metabolic tumor volume (TMTV) automatically.
- Aids in the efficiency of medical professionals by automating tedious tasks.
- Provides information that can be used in addition to standard image interpretation.
- Raises no new questions of safety or effectiveness according to the FDA.
- FDA-cleared.
Limitations
- Does not screen for or diagnose lymphoma.
- Intended only for patients already diagnosed with FDG-avid lymphoma.
- The physician has the option to accept/reject the output but cannot modify it.
- Requires review by a radiologist, who makes the final decision on image interpretation.
- Limited information available from independent reviews (e.g., Reddit, G2, Capterra).
- Decision date for FDA clearance is May 30, 2025, suggesting it is a relatively new or upcoming product.
Based on reviews from: parikhradiology.com, fda.gov, healthaidb.com, kpmg.com
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Opulus Lymphoma Precision
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Opulus Lymphoma Precision.





